JP5062872B2 - Orally disintegrating tablets with reduced unpleasant taste - Google Patents
Orally disintegrating tablets with reduced unpleasant taste Download PDFInfo
- Publication number
- JP5062872B2 JP5062872B2 JP2003292731A JP2003292731A JP5062872B2 JP 5062872 B2 JP5062872 B2 JP 5062872B2 JP 2003292731 A JP2003292731 A JP 2003292731A JP 2003292731 A JP2003292731 A JP 2003292731A JP 5062872 B2 JP5062872 B2 JP 5062872B2
- Authority
- JP
- Japan
- Prior art keywords
- drug
- orally disintegrating
- particles
- granule
- unpleasant taste
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 235000019640 taste Nutrition 0.000 title claims description 16
- 239000006191 orally-disintegrating tablet Substances 0.000 title claims description 15
- 230000002829 reductive effect Effects 0.000 title claims description 8
- 239000003826 tablet Substances 0.000 claims description 28
- 239000003814 drug Substances 0.000 claims description 24
- 229940079593 drug Drugs 0.000 claims description 23
- 239000008187 granular material Substances 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000001856 Ethyl cellulose Substances 0.000 claims description 12
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 12
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 12
- 229920001249 ethyl cellulose Polymers 0.000 claims description 12
- 210000000214 mouth Anatomy 0.000 claims description 9
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 claims description 9
- 235000012239 silicon dioxide Nutrition 0.000 claims description 9
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 8
- 229960000913 crospovidone Drugs 0.000 claims description 8
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 8
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 8
- 238000000576 coating method Methods 0.000 claims description 6
- 235000000346 sugar Nutrition 0.000 claims description 4
- 150000005846 sugar alcohols Chemical class 0.000 claims description 4
- 239000011248 coating agent Substances 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 2
- 239000001341 hydroxy propyl starch Substances 0.000 claims description 2
- 235000013828 hydroxypropyl starch Nutrition 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000007900 aqueous suspension Substances 0.000 claims 1
- 238000005507 spraying Methods 0.000 claims 1
- 239000002245 particle Substances 0.000 description 37
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 24
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 18
- 235000019658 bitter taste Nutrition 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 235000010355 mannitol Nutrition 0.000 description 12
- 235000019359 magnesium stearate Nutrition 0.000 description 9
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 8
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 8
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 8
- 229960001596 famotidine Drugs 0.000 description 8
- 229940041616 menthol Drugs 0.000 description 8
- 108010011485 Aspartame Proteins 0.000 description 7
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 7
- 235000010357 aspartame Nutrition 0.000 description 7
- 239000000605 aspartame Substances 0.000 description 7
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 7
- 229960003438 aspartame Drugs 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 239000000454 talc Substances 0.000 description 7
- 229910052623 talc Inorganic materials 0.000 description 7
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 7
- 229920002261 Corn starch Polymers 0.000 description 6
- 244000246386 Mentha pulegium Species 0.000 description 6
- 235000016257 Mentha pulegium Nutrition 0.000 description 6
- 235000004357 Mentha x piperita Nutrition 0.000 description 6
- 239000008120 corn starch Substances 0.000 description 6
- 235000001050 hortel pimenta Nutrition 0.000 description 6
- 238000005469 granulation Methods 0.000 description 4
- 230000003179 granulation Effects 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 3
- 238000004080 punching Methods 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000000748 compression moulding Methods 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229960001375 lactose Drugs 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000019596 Masking bitterness Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000008123 high-intensity sweetener Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 235000013615 non-nutritive sweetener Nutrition 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 229920003176 water-insoluble polymer Polymers 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Description
本発明は口腔内で速やかに崩壊する口腔内崩壊錠剤において、苦味などの不快な味を有する薬物を被覆することにより、不快な味を低減した口腔内崩壊錠剤に関する。 The present invention relates to an orally disintegrating tablet in which an unpleasant taste is reduced by coating an orally disintegrating tablet rapidly disintegrating in the oral cavity with a drug having an unpleasant taste such as a bitter taste.
従来、経口医薬品の剤形として飲みやすい剤形、特に高齢者や小児に適した取り扱いやすい剤形の開発が求められている。経口製剤として広く使用されている錠剤やカプセル剤は、嚥下力が弱い高齢者や小児の場合、飲み込みにくいという問題がある。顆粒剤、散剤においては、服用時にむせたり、口腔内に残留しやすく不快感が残ることが多い。またこれらの剤形は服用時に必ず水が必要となり、水が用意できない場合は服用できないのも問題であった。 Conventionally, there has been a demand for the development of easy-to-drink dosage forms for oral pharmaceuticals, particularly easy-to-handle dosage forms suitable for the elderly and children. Tablets and capsules widely used as oral preparations have a problem that they are difficult to swallow in the case of elderly people and children with weak swallowing ability. Granules and powders tend to remain uncomfortable because they tend to be taken when taken or remain in the oral cavity. In addition, these dosage forms always require water at the time of taking, and it was a problem that they could not be taken when water was not available.
しかし苦味などの不快な味を有する薬物の口腔内崩壊錠剤においては、口腔内で速やかに崩壊するため、苦味などの不快な味が口腔内で暴露されてしまう。また水なしで服用するため、その不快な味は長時間にわたって残存する。これらの点においては、通常の錠剤よりも口腔内崩壊錠剤の方が服用しづらい。 However, since an orally disintegrating tablet of a drug having an unpleasant taste such as a bitter taste disintegrates rapidly in the oral cavity, an unpleasant taste such as a bitter taste is exposed in the oral cavity. Moreover, since it is taken without water, the unpleasant taste remains for a long time. In these respects, orally disintegrating tablets are more difficult to take than ordinary tablets.
この問題を解決すべく先行技術に関して、特開２０００−１５９６９１はメントールと甘味剤を組み合わせて配合することにより、苦味をマスキングする方法である。特開２００１−７２５７８も精油と高甘味度甘味剤を組み合わせて配合したものである。これらはともに苦味を有する薬物に対して被覆をしていないため、完全に苦味をマスキングすることはできなかった。特許３４１５８３５には、苦味を有する薬物と水不溶性高分子を噴霧乾燥されてなる粒子に、これと別に製造した速放性顆粒を混合して圧縮成形した苦味を低減した口腔内崩壊錠剤が記載されている。この方法において苦味は低減されているものの、製造上噴霧乾燥は決して簡便な方法とは言えず、多くのパラメータにより制御が必要になってくる。 Regarding the prior art to solve this problem, Japanese Patent Application Laid-Open No. 2000-159691 is a method for masking bitterness by blending menthol and sweeteners. Japanese Patent Application Laid-Open No. 2001-72578 is also a combination of an essential oil and a high-intensity sweetener. Since both of these did not coat a drug having a bitter taste, it was not possible to completely mask the bitter taste. Japanese Patent No. 3415835 describes an orally disintegrating tablet with reduced bitterness obtained by compression-molding particles prepared by spray-drying a drug having a bitter taste and a water-insoluble polymer separately from the particles. ing. Although bitterness is reduced in this method, spray drying is not a simple method for production, and control is required by many parameters.
本発明者らは、苦味などの不快な味を低減した口腔内速崩壊錠剤について鋭意研究を行った結果、（ａ）賦形剤と混合した苦味などの不快な味を有する薬物をエチルセルロースで造粒もしくは被覆してなる薬物含有顆粒、及び（ｂ）糖又は糖アルコールを水に不溶であるが親水性の造粒成分で造粒もしくは被覆してなる薬物不含顆粒、との混合圧縮成形物である、不快な味を低減した口腔内崩壊錠剤が得られ、本発明を完成するに至った。 As a result of diligent research on an orally rapidly disintegrating tablet with reduced unpleasant taste such as bitterness, the present inventors made (a) a drug having an unpleasant taste such as a bitter taste mixed with an excipient with ethyl cellulose. A granulated or coated drug-containing granule, and (b) a drug-free granule formed by granulating or coating a sugar or sugar alcohol in water but with a hydrophilic granulating component. Thus, an orally disintegrating tablet with reduced unpleasant taste was obtained, and the present invention was completed.
本発明における造粒もしくは被覆方法は任意であるが、通常よく用いられる流動層造粒被覆方法が操作が簡便なため好ましい。流動層造粒被覆方法は流動性の低い不快な味を有する薬物を口腔内崩壊錠に製剤加工する場合にも適用でき、不快な味を隠蔽することができるばかりでなく、流動性を改善することができる。薬物含有顆粒（ａ）および薬物不含顆粒（ｂ）の平均粒子径は約５０〜１５０μｍ，好ましくは５０〜１００μｍであることが適当であり、これにより口腔内でザラツキおよび異物感を全く感じさせない口腔内崩壊錠剤とすることができる。 Although the granulation or coating method in the present invention is arbitrary, the fluidized bed granulation coating method that is usually used is preferred because the operation is simple. The fluidized bed granulation coating method can also be applied to the preparation of orally disintegrating drugs with low fluidity and an unpleasant taste, and can not only hide the unpleasant taste but also improve the fluidity. be able to. The average particle size of the drug-containing granule (a) and the drug-free granule (b) is about 50 to 150 μm, preferably 50 to 100 μm, so that no roughness and foreign body sensation are felt in the oral cavity. It can be an orally disintegrating tablet.
薬物含有顆粒（ａ）に対する薬物不含顆粒（ｂ）の混合割合は５０重量％以上が適当である。これより少ないと口腔内崩壊錠として、口腔内崩壊速度と錠剤硬度の間の最適なバランスを確立することが困難になる。 The mixing ratio of the drug-free granule (b) to the drug-containing granule (a) is suitably 50% by weight or more. If it is less than this, as an orally disintegrating tablet, it becomes difficult to establish an optimal balance between the orally disintegrating rate and the tablet hardness.
薬物に対するエチルセルロースの重量比は、０．１：１ないし２：１の範囲が適当であるが、好ましくは０．２：１ないし１：１である。また薬物含有顆粒（ａ）中に占めるエチルセルロースの割合は２ないし５０重量％が適当であるが、好ましくは５ないし３０重量％である。ともにこれらは少なすぎると苦味などの不快な味が低減できず、多すぎるとバイオアベイラビリティーが低下するので好ましくない。 The weight ratio of ethylcellulose to drug is suitably in the range of 0.1: 1 to 2: 1, but is preferably 0.2: 1 to 1: 1. The proportion of ethylcellulose in the drug-containing granule (a) is suitably 2 to 50% by weight, preferably 5 to 30% by weight. In both cases, if the amount is too small, unpleasant taste such as bitterness cannot be reduced, and if too large, bioavailability is lowered, which is not preferable.
薬物含有顆粒（ａ）には他に、流動性向上のためにタルクやステアリン酸マグネシウムを、遮光性のために酸化チタンを含有させることができる。 In addition, the drug-containing granules (a) may contain talc or magnesium stearate for improving fluidity and titanium oxide for light shielding.
また本発明は薬物含有顆粒（ａ）を直接、水に不溶であるが親水性の造粒成分で造粒もしくは被覆して圧縮成形することもできる。 In the present invention, the drug-containing granule (a) can be directly compressed by being granulated or coated with a hydrophilic granulation component which is insoluble in water.
ここで用いられる水に不溶であるが親水性の造粒成分の例は、デンプン、クロスポビドン、微粒子無水ケイ酸またはヒドロキシプロピルスターチなどである。これらは糖または糖アルコール等の賦形成分とは独立して存在し、親水性のため唾液の水分が錠剤内部まで速やかに浸透するのを助け、錠剤全体の口腔内での自壊を助ける。 Examples of water-insoluble but hydrophilic granulating ingredients used here are starch, crospovidone, particulate silicic acid anhydride or hydroxypropyl starch. These exist independently of the ingredients such as sugars or sugar alcohols, and since they are hydrophilic, they help the saliva water to permeate quickly into the tablet and help the whole tablet self-destruct in the oral cavity.
打錠による圧縮成形に際しては、混合物にステアリン酸マグネシウムや軽質無水ケイ酸のような滑沢剤が添加される。また必要に応じ、アスパルテームのような甘味剤及びメントールのような矯味剤を添加してもよい。 In compression molding by tableting, a lubricant such as magnesium stearate or light anhydrous silicic acid is added to the mixture. If necessary, a sweetening agent such as aspartame and a corrigent such as menthol may be added.
限定を意図しない以下の実施例によって本発明を具体的に説明する。これら実施例においては、薬物としてファモチジンを用いたが、本発明は苦味などの不快な味を有する他の薬物に対しても同様に適用し得ることは自明である。 The invention is illustrated by the following examples which are not intended to be limiting. In these examples, famotidine was used as a drug, but it is obvious that the present invention can be applied to other drugs having an unpleasant taste such as bitter taste as well.
実施例１
ファモチジン２００ｇ及びＤ−マンニトール２６０ｇをマルチブレックスＭＰ−０１に投入し、エチルセルロース４０ｇ、酸化チタン５０ｇ及びタルク５０ｇを９０％エタノール８００ｍｌに分散溶解した溶液でコーティングした。この得られた粒子をＡ粒子とする。
一方、Ｄ−マンニトール７７６ｇをＭＰ−０１に投入し、トウモロコシデンプン２８８ｇ及びクロスポビドン２４ｇを水１１００mlに分散した溶液でコーティングした。この得られた粒子をＢ粒子とする。
Ａ粒子６０ｇに対し、Ｂ粒子１０８．８ｇ、メントールミクロン２．０ｇ、ペパーミントミクロン１．０ｇ、軽質無水ケイ酸０．３ｇ及びアスパルテーム４．５ｇを加え、ＰＥ袋にて混合した。更にステアリン酸マグネシウム１．４ｇを加え、混合し、打錠末した。
ロータリー式打錠機を用いて打錠圧６．５ｋＮにて打錠し錠径８．５ｍｍ、錠剤重量１７８ｍｇの錠剤を得た。
Example 1
200 g of famotidine and 260 g of D-mannitol were added to Multibrex MP-01, and coated with a solution obtained by dispersing and dissolving 40 g of ethyl cellulose, 50 g of titanium oxide and 50 g of talc in 800 ml of 90% ethanol. The obtained particles are referred to as A particles.
On the other hand, 776 g of D-mannitol was added to MP-01 and coated with a solution in which 288 g of corn starch and 24 g of crospovidone were dispersed in 1100 ml of water. The obtained particles are referred to as B particles.
108.8 g of B particles, 2.0 g of menthol micron, 1.0 g of peppermint micron, 0.3 g of light anhydrous silicic acid and 4.5 g of aspartame were added to 60 g of A particles, and mixed in a PE bag. Further, 1.4 g of magnesium stearate was added, mixed and tableted.
Tableting was performed using a rotary tableting machine at a tableting pressure of 6.5 kN to obtain a tablet having a tablet diameter of 8.5 mm and a tablet weight of 178 mg.
実施例２
ファモチジン２００ｇ及びＤ−マンニトール２４０ｇをマルチプレックスＭＰ−０１に投入し、エチルセルロース６０ｇ、酸化チタン５０ｇ及びタルク５０ｇを９０％エタノール１２００ｍｌに分散溶解した溶液でコーティングした。この得られた粒子をＡ粒子とする。
一方、Ｄ−マンニトール７７６ｇをＭＰ−０１に投入し、トウモロコシデンプン２８８ｇ及びクロスポピドン２４ｇを水１１００ｍｌに分散した溶液でコーティングした。この得られた粒子をＢ粒子とする。
Ａ粒子６０ｇに対し、Ｂ粒子１０８．８ｇ、メントールミクロン２．０ｇ、ペパーミントミクロン１．０ｇ、軽質無水ケイ酸０．３ｇ及びアスパルテーム２．５ｇを加え、ＰＥ袋にて混合した。更にステアリン酸マグネシウム１．４ｇを加え、混合し、打錠末とした。
ロータリー式打錠機を用いて打錠圧６．０ｋＮにて打径８．５ｍｍ、錠剤重量１７６ｍｇの錠剤を得た。
Example 2
200 g of famotidine and 240 g of D-mannitol were put into multiplex MP-01, and coated with a solution obtained by dispersing and dissolving 60 g of ethylcellulose, 50 g of titanium oxide and 50 g of talc in 1200 ml of 90% ethanol. The obtained particles are referred to as A particles.
On the other hand, 776 g of D-mannitol was added to MP-01 and coated with a solution in which 288 g of corn starch and 24 g of crospovidone were dispersed in 1100 ml of water. The obtained particles are referred to as B particles.
To 60 g of A particles, 108.8 g of B particles, 2.0 g of menthol micron, 1.0 g of peppermint micron, 0.3 g of light anhydrous silicic acid and 2.5 g of aspartame were added and mixed in a PE bag. Further, 1.4 g of magnesium stearate was added and mixed to obtain a tableting powder.
Using a rotary tableting machine, tablets with a tableting diameter of 8.5 mm and a tablet weight of 176 mg were obtained at a tableting pressure of 6.0 kN.
実施例３
ファモチジン２００ｇ及びＤ−マンニトール２１０ｇをマルチプレックスＭＰ−０１に投入し、エチルセルロース９０ｇ、酸化チタン５０ｇ及びタルク５０ｇを９０％エタノール１６００ｍｌに分散溶解した溶液でコーティングした。この得られた粒子をＡ粒子とする。
一方、Ｄ−マンニトール７７６ｇをＭＰ−０１に投入し、トウモロコシデンプン２８８ｇ及びクロスポピドン２４ｇを水１１００ｍｌに分散した溶液でコーティングした。この得られた粒子をＢ粒子とする。
Ａ粒子６０ｇに対し、Ｂ粒子１０８．８ｇ、メントールミクロン２．０ｇ、ペパーミントミクロン１．０ｇ、軽質無水ケイ酸０．３ｇ及びアスパルテーム４．５ｇを加え、ＰＥ袋にて混合した。更にステアリン酸マグネシウム１．４ｇを加え、混合し、打錠末とした。
ロータリー式打錠機を用いて打錠圧６．５ｋＮにて打径８．５ｍｍ、錠剤重量１７８ｍｇの錠剤を得た。
Example 3
200 g of famotidine and 210 g of D-mannitol were put into multiplex MP-01, and coated with a solution in which 90 g of ethyl cellulose, 50 g of titanium oxide and 50 g of talc were dispersed and dissolved in 1600 ml of 90% ethanol. The obtained particles are referred to as A particles.
On the other hand, 776 g of D-mannitol was added to MP-01 and coated with a solution in which 288 g of corn starch and 24 g of crospovidone were dispersed in 1100 ml of water. The obtained particles are referred to as B particles.
108.8 g of B particles, 2.0 g of menthol micron, 1.0 g of peppermint micron, 0.3 g of light anhydrous silicic acid and 4.5 g of aspartame were added to 60 g of A particles, and mixed in a PE bag. Further, 1.4 g of magnesium stearate was added and mixed to obtain a tableting powder.
Using a rotary tableting machine, tablets with a punching diameter of 8.5 mm and a tablet weight of 178 mg were obtained at a tableting pressure of 6.5 kN.
実施例４
ファモチジン２００ｇ及びＤ−マンニトール１９０ｇをマルチプレックスＭＰ−０１に投入し、エチルセルロース１１０ｇ、酸化チタン５０ｇ及びタルク５０ｇを９０％エタノール２２００ｍｌに分散溶解した溶液でコーティングした。この得られた粒子をＡ粒子とする。
一方、Ｄ−マンニトール７７６ｇをＭＰ−０１に投入し、トウモロコシデンプン２８８ｇ及びクロスポピドン２４ｇを水１１００ｍｌに分散した溶液でコーティングした。この得られた粒子をＢ粒子とする。
Ａ粒子６０ｇに対し、Ｂ粒子１０８．８ｇ、メントールミクロン２．０ｇ、ペパーミントミクロン１．０ｇ、軽質無水ケイ酸０．３ｇ及びアスパルテーム４．５ｇを加え、ＰＥ袋にて混合した。更にステアリン酸マグネシウム１．４ｇを加え、混合し、打錠末とした。
ロータリー式打錠機を用いて打錠圧６．５ｋＮにて打径８．５ｍｍ、錠剤重量１７８ｍｇの錠剤を得た。
Example 4
200 g of famotidine and 190 g of D-mannitol were put into multiplex MP-01, and coated with a solution in which 110 g of ethyl cellulose, 50 g of titanium oxide and 50 g of talc were dispersed and dissolved in 2200 ml of 90% ethanol. The obtained particles are referred to as A particles.
On the other hand, 776 g of D-mannitol was added to MP-01 and coated with a solution in which 288 g of corn starch and 24 g of crospovidone were dispersed in 1100 ml of water. The obtained particles are referred to as B particles.
108.8 g of B particles, 2.0 g of menthol micron, 1.0 g of peppermint micron, 0.3 g of light anhydrous silicic acid and 4.5 g of aspartame were added to 60 g of A particles, and mixed in a PE bag. Further, 1.4 g of magnesium stearate was added and mixed to obtain a tableting powder.
Using a rotary tableting machine, tablets with a punching diameter of 8.5 mm and a tablet weight of 178 mg were obtained at a tableting pressure of 6.5 kN.
実施例５
ファモチジン２００ｇ及びＤ−マンニトール１８０ｇをマルチプレックスＭＰ−０１に投入し、エチルセルロース１２０ｇ、酸化チタン５０ｇ及びタルク５０ｇを９０％エタノール２４００ｍｌに分散溶解した溶液でコーティングした。この得られた粒子をＡ粒子とする。
一方、Ｄ−マンニトール７７６ｇをＭＰ−０１に投入し、トウモロコシデンプン２８８ｇ及びクロスポピドン２４ｇを水１１００ｍｌに分散した溶液でコーティングした。この得られた粒子をＢ粒子とする。
Ａ粒子６０ｇに対し、Ｂ粒子１０８．８ｇ、メントールミクロン２．０ｇ、ペパーミントミクロン１．０ｇ、軽質無水ケイ酸０．３ｇ及びアスパルテーム４．５ｇを加え、ＰＥ袋にて混合した。更にステアリン酸マグネシウム１．４ｇを加え、混合し、打錠末とした。
ロータリー式打錠機を用いて打錠圧７．０ｋＮにて打径８．５ｍｍ、錠剤重量１７８ｍｇの錠剤を得た。
Example 5
200 g of famotidine and 180 g of D-mannitol were put into multiplex MP-01, and coated with a solution obtained by dispersing and dissolving 120 g of ethyl cellulose, 50 g of titanium oxide and 50 g of talc in 2400 ml of 90% ethanol. The obtained particles are referred to as A particles.
On the other hand, 776 g of D-mannitol was added to MP-01 and coated with a solution in which 288 g of corn starch and 24 g of crospovidone were dispersed in 1100 ml of water. The obtained particles are referred to as B particles.
108.8 g of B particles, 2.0 g of menthol micron, 1.0 g of peppermint micron, 0.3 g of light anhydrous silicic acid and 4.5 g of aspartame were added to 60 g of A particles, and mixed in a PE bag. Further, 1.4 g of magnesium stearate was added and mixed to obtain a tableting powder.
Using a rotary tableting machine, tablets with a punching diameter of 8.5 mm and a tablet weight of 178 mg were obtained at a tableting pressure of 7.0 kN.
実施例６
ファモチジン２００ｇ及びＤ−マンニトール１９０ｇをマルチプレックスＭＰ−０１に投入し、エチルセルロース１１０ｇ、酸化チタン５０ｇ及びタルク５０ｇを９０％エタノール２２００ｍｌに分散溶解した溶液でコーティングした。この得られた粒子をＡ粒子とする。
得られたＡ粒子３００ｇとＤ−マンニトール３８８ｇをＭＰ−０１に投入し、トウモロコシデンプン１４４ｇ及びクロスポビドン１２ｇを水５２０ｍｌに分散した溶液でコーティングした。
この粒子１６８．８ｇ、メントールミクロン２．０ｇ、ペパーミントミクロン１．０ｇ
、軽質無水ケイ酸０．３ｇ及びアスパルテーム４．５ｇを加え、ＥＰ袋にて混合した。更にステアリン酸マグネシウム１．４ｇを加え、混合し、打錠末とした。
ロータリー式打錠機を用いて打錠圧６．５ｋＮにて打錠し、錠径８．５ｍｍ、錠剤重量１７８ｍｇの錠剤を得た。
Example 6
200 g of famotidine and 190 g of D-mannitol were put into multiplex MP-01, and coated with a solution in which 110 g of ethyl cellulose, 50 g of titanium oxide and 50 g of talc were dispersed and dissolved in 2200 ml of 90% ethanol. The obtained particles are referred to as A particles.
300 g of the obtained A particles and 388 g of D-mannitol were put into MP-01, and coated with a solution in which 144 g of corn starch and 12 g of crospovidone were dispersed in 520 ml of water.
168.8 g of this particle, menthol micron 2.0 g, peppermint micron 1.0 g
Then, 0.3 g of light anhydrous silicic acid and 4.5 g of aspartame were added and mixed in an EP bag. Further, 1.4 g of magnesium stearate was added and mixed to obtain a tableting powder.
Tableting was performed with a tableting pressure of 6.5 kN using a rotary tableting machine to obtain tablets with a tablet diameter of 8.5 mm and a tablet weight of 178 mg.
比較例１
ファモチジン４０ｇ、結晶セルロース（アビセルＰＨ１０１）１００ｇ及び乳糖（ダイラクトーズＳ）３２７６ｇをボーレ混合機にて混合した、更にステアリン酸マグネシウム４ｇを加え、混合し、打錠末とした。
ロータリー式打錠機を用いて打錠圧６ｋＮにて打錠し、錠径８．０ｍｍ、錠剤重量２１０ｍｇの錠剤を得た。
Comparative Example 1
40 g of famotidine, 100 g of crystalline cellulose (Avicel PH101) and 3276 g of lactose (Dilactose S) were mixed with a Boule mixer, and further 4 g of magnesium stearate was added and mixed to obtain a tableting powder.
Tableting was performed with a tableting pressure of 6 kN using a rotary tableting machine to obtain tablets with a tablet diameter of 8.0 mm and a tablet weight of 210 mg.
官能試験
実施例及び比較例で得た錠剤をパネラー５人を用いて、薬物の苦味抑制効果の官能試験を行った。錠剤を口に含み崩壊させ、６０秒以上口腔内にとどめ、その苦味を以下の６段階で評価してもらった。
Sensory test The sensory test of the bitterness inhibitory effect of the drug was performed on the tablets obtained in Examples and Comparative Examples using 5 panelists. The tablet was disintegrated in the mouth and kept in the oral cavity for 60 seconds or longer, and the bitterness was evaluated in the following 6 levels.
本発明は、苦味などの不快な味を有する薬物を口腔内崩壊錠剤へ製剤加工する場合に有用である。 The present invention is useful when a drug having an unpleasant taste such as a bitter taste is processed into an orally disintegrating tablet.
Claims (4)
前記薬物不含顆粒が、糖または糖アルコールの流動層へ、デンプン、クロスポビドン、微粒子無水ケイ酸またはヒドロキシプロピルスターチから選ばれた水に不溶であるが、親水性の錠剤の口腔内崩壊を補助する成分の水懸濁液を噴霧することによって製造された顆粒であることを特徴とする口腔内崩壊錠剤。 (A) a drug-containing granule obtained by granulating or coating a drug having an unpleasant taste mixed with an excipient with ethyl cellulose, and (b) an oral cavity of a hydrophilic tablet in which sugar or sugar alcohol is insoluble in water An orally disintegrating tablet with reduced unpleasant taste, which is a mixed compression-molded product with a drug-free granule that is granulated with a component that assists in disintegration,
The drug-free granules are insoluble in water selected from starch, crospovidone, particulate silicic acid anhydride or hydroxypropyl starch into a sugar or sugar alcohol fluidized bed, but aid in the oral disintegration of hydrophilic tablets An orally disintegrating tablet, wherein the tablet is a granule produced by spraying an aqueous suspension of the component to be sprayed.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003292731A JP5062872B2 (en) | 2003-08-13 | 2003-08-13 | Orally disintegrating tablets with reduced unpleasant taste |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003292731A JP5062872B2 (en) | 2003-08-13 | 2003-08-13 | Orally disintegrating tablets with reduced unpleasant taste |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005060309A JP2005060309A (en) | 2005-03-10 |
| JP5062872B2 true JP5062872B2 (en) | 2012-10-31 |
Family
ID=34369952
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003292731A Expired - Lifetime JP5062872B2 (en) | 2003-08-13 | 2003-08-13 | Orally disintegrating tablets with reduced unpleasant taste |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP5062872B2 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015008825A1 (en) | 2013-07-19 | 2015-01-22 | 株式会社三和化学研究所 | Orally disintegrating tablet |
| WO2017217494A1 (en) | 2016-06-16 | 2017-12-21 | 東和薬品株式会社 | Orally disintegrating tablet |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5228359B2 (en) | 2007-04-12 | 2013-07-03 | ニプロ株式会社 | Active ingredient particles, process for producing the same and orally disintegrating tablets |
| KR101753411B1 (en) * | 2008-11-25 | 2017-07-03 | 미쓰비시 타나베 파마 코퍼레이션 | Orally rapidly disintegrating tablet, and process for producing same |
| NZ605562A (en) | 2010-07-09 | 2013-11-29 | Teijin Pharma Ltd | Deuterated benzylbenzene derivatives and methods of use |
| FI126168B (en) | 2012-09-18 | 2016-07-29 | Novaldmedical Ltd Oy | Process for coating pharmaceutical substrates |
| WO2019143744A1 (en) | 2018-01-16 | 2019-07-25 | Applied Materials, Inc. | Metal oxide encapsulated drug compositions and methods of preparing the same |
| TW202216124A (en) | 2020-10-02 | 2022-05-01 | 美商應用材料股份有限公司 | Low temperature process for preparing silicon oxide coated pharmaceuticals |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2785538B1 (en) * | 1998-11-06 | 2004-04-09 | Prographarm Laboratoires | PERFECTED QUICK DELIVERY TABLET |
| JP4802436B2 (en) * | 2000-04-12 | 2011-10-26 | Ｍｓｄ株式会社 | Orally disintegrating composition and orally disintegrating preparation |
| JP5138856B2 (en) * | 2001-06-20 | 2013-02-06 | 武田薬品工業株式会社 | Tablet manufacturing method |
-
2003
- 2003-08-13 JP JP2003292731A patent/JP5062872B2/en not_active Expired - Lifetime
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015008825A1 (en) | 2013-07-19 | 2015-01-22 | 株式会社三和化学研究所 | Orally disintegrating tablet |
| WO2017217494A1 (en) | 2016-06-16 | 2017-12-21 | 東和薬品株式会社 | Orally disintegrating tablet |
| US10881610B2 (en) | 2016-06-16 | 2021-01-05 | Towa Pharmaceutical Co., Ltd. | Orally disintegrating tablet |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2005060309A (en) | 2005-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2347968T3 (en) | SOLID PREPARATION THAT DISAPPEARS RAPIDLY. | |
| JP6092936B2 (en) | Method for producing orally disintegrating tablets | |
| JP4749668B2 (en) | Orally dispersible tablet having high homogeneity and method for preparing the same | |
| JP5296456B2 (en) | Irbesartan-containing pharmaceutical composition with good dissolution and orally disintegrating tablet | |
| JP4740740B2 (en) | Drug-containing particles and solid preparation containing the particles | |
| JP5342028B2 (en) | Orally disintegrating tablets | |
| WO2000078292A1 (en) | Quickly disintegrating solid preparations | |
| JP2001058944A (en) | Rapidly disintegrating solid formulation | |
| JP4551627B2 (en) | Method for producing orally disintegrating tablets | |
| JP5062871B2 (en) | Orally disintegrating tablets with reduced bitterness | |
| JP2017141299A (en) | Irbesartan-containing pharmaceutical composition showing excellent elution, and orally disintegrable tablet | |
| JP2003034655A (en) | Fast degradable solid tablet | |
| JP5062872B2 (en) | Orally disintegrating tablets with reduced unpleasant taste | |
| JP4358117B2 (en) | Orally disintegrating tablets | |
| JP2013237651A (en) | Orally-disintegrating tablet of pitavastatin | |
| JP2010241760A (en) | Tablet quickly disintegrable in oral cavity that has unpleasant taste reduced, and method for preparing the same | |
| JP5978335B2 (en) | Irbesartan-containing pharmaceutical composition with good dissolution and orally disintegrating tablet | |
| JP5584509B2 (en) | Orally disintegrating tablets | |
| WO2022102457A1 (en) | Linagliptin-containing orally disintegrating tablet | |
| JP5275815B2 (en) | Orally disintegrating tablets and bitterness-suppressing preparations containing risperidone | |
| TWI644688B (en) | Method for producing orally disintegrating lozenge containing disintegrating particle composition | |
| JP6151413B2 (en) | Irbesartan-containing pharmaceutical composition with good dissolution and orally disintegrating tablet | |
| JP5714652B2 (en) | Irbesartan-containing pharmaceutical composition with good dissolution and orally disintegrating tablet | |
| JP2009179603A (en) | Quickly disintegrating tablet in oral cavity, and method for producing the same | |
| WO2019098327A1 (en) | Orally disintegrating tablet having suppressed bitterness of fast dissolving drug |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060629 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20090722 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090804 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090911 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100112 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100405 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20100427 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20100611 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120806 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 5062872 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150817 Year of fee payment: 3 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |